Yayın:
Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience

Sadeleştirilmiş öğe sayfası
dc.contributor.authorBirtaş, Elif
dc.contributor.authorAyşe Salihoğlu
dc.contributor.authorTeoman Soysal
dc.contributor.authorÌhsan Karadoǧan
dc.contributor.authorSemra Paydaş
dc.contributor.authorEvren Özdemir
dc.contributor.authorBirol Yıldız
dc.contributor.authorNuri Karadurmuş
dc.contributor.authorLeylagül Kaynar
dc.contributor.authorMünci Yağcı
dc.contributor.authorVildan Özkocaman
dc.contributor.authorPervin Topçuoğlu
dc.contributor.authorMuhi̇t Özcan
dc.contributor.authorElif Birtaş
dc.contributor.authorHakan Göker
dc.contributor.authorBurhan Ferhanoğlu
dc.contributor.orcid0000-0002-3040-4052
dc.contributor.orcid0000-0002-8758-7945
dc.contributor.orcid0000-0002-7417-2118
dc.contributor.orcid0000-0003-4642-3693
dc.contributor.orcid0000-0001-7754-4135
dc.contributor.orcid0000-0001-8920-6467
dc.contributor.orcid0000-0003-3291-8062
dc.contributor.orcid0000-0002-2035-9462
dc.contributor.orcid0000-0002-0458-2920
dc.contributor.orcid0000-0003-0014-7398
dc.contributor.orcid0000-0002-4834-3585
dc.contributor.orcid0000-0002-1326-1918
dc.contributor.orcid0000-0002-1039-7756
dc.contributor.orcid0000-0002-4257-549X
dc.date.accessioned2025-11-13T11:25:11Z
dc.date.issued2019-12-17
dc.identifier.doihttps://doi.org/10.1007/s00277-019-03899-1
dc.identifier.endpage307
dc.identifier.issn0939-5555
dc.identifier.issue2
dc.identifier.openalexW2996417306
dc.identifier.startpage301
dc.identifier.urihttps://hdl.handle.net/11421/6729
dc.identifier.urihttps://doi.org/10.1007/s00277-019-03899-1
dc.identifier.volume99
dc.language.isoen
dc.relation.ispartofAnnals of Hematology
dc.rightsrestrictedAccess
dc.subjectBrentuximab vedotin
dc.subjectInternal medicine
dc.subjectHodgkin lymphoma
dc.subjectOncology
dc.subjectMedicine
dc.subjectHematology
dc.subjectLymphoma
dc.subjectCenter (category theory)
dc.subjectRefractory (planetary science)
dc.subjectBiology
dc.subjectChemistry
dc.titleLong-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5083835943

Dosyalar

Koleksiyonlar

Publications